Journal Article

The future of diagnosis in clinical neurosciences: Comparing multiple sclerosis and schizophrenia

Bassetti, Claudio, Dom, Geert, Szulc, Agata, Gaebel, Wolfgang, Kärkkäinen, Hilkka, Falkai, Peter, Volpe, Umberto, Papiol, Sergi, Decraene, Andre, Misiak, Błażej, Gorwood, Philip, Chan, Andrew, Samochowiec, Jerzy, Kurimay, Tamas, Kowalski, Krzysztof, Wisse, Jan, Fiorillo, Andrea

2023

Overview

The ongoing developments of psychiatric classification systems have largely improved reliability of diagnosis, including that of schizophrenia. However, with an unknown pathophysiology and lacking biomarkers, its validity still remains low, requiring further advancements. Research has helped establish multiple sclerosis (MS) as the central nervous system (CNS) disorder with an established pathophysiology, defined biomarkers and therefore good validity and significantly improved treatment options. Before proposing next steps in research that aim to improve the diagnostic process of schizophrenia, it is imperative to recognize its clinical heterogeneity. Indeed, individuals with schizophrenia show high interindividual variability in terms of symptomatic manifestation, response to treatment, course of illness and functional outcomes. There is also a multiplicity of risk factors that contribute to the development of schizophrenia. Moreover, accumulating evidence indicates that several dimensions of psychopathology and risk factors cross current diagnostic categorizations. Schizophrenia shares a number of similarities with MS, which is a demyelinating disease of the CNS. These similarities appear in the context of age of onset, geographical distribution, involvement of immune-inflammatory processes, neurocognitive impairment and various trajectories of illness course. This article provides a critical appraisal of diagnostic process in schizophrenia, taking into consideration advancements that have been made in the diagnosis and management of MS. Based on the comparison between the two disorders, key directions for studies that aim to improve diagnostic process in schizophrenia are formulated. All of them converge on the necessity to deconstruct the psychosis spectrum and adopt dimensional approaches with deep phenotyping to refine current diagnostic boundaries.

• Publisher: Royal College of Psychiatrists,Cambridge University Press,Cambridge University press
• Subject: [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology / Age / Biomarkers / Bipolar disorder / diagnosis / diagnosis; dimension; multiple sclerosis; neurology; psychiatry; psychopathology; reliability; schizophrenia; validity / dimension / Disease / EPA Position Paper / Gender differences / Health risk assessment / Human health and pathology / Human medicine / Humans / Life Sciences / Medical imaging / Mental disorders / Minority & ethnic groups / Multiple Sclerosis / Multiple Sclerosis - diagnosis / Neuroimaging / Neurology / Neurosciences / Psychiatry / Psychopathology / Psychosis / Psychotic Disorders / Psychotic Disorders - psychology / RC435-571 / reliability / Reproducibility of Results / Risk factors / Schizophrenia / Schizophrenia - diagnosis / Spinal cord / Validity